You searched for vision loss - Page 3 of 9

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors

August 27, 2023 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Many avenues are being pursued to get stem cell therapy to the clinic for eye conditions. These different approaches employ a variety of stem cell types. In some cases, such as with iPS cells, the stem cells themselves are not transplanted. Instead, the iPS cells are used to make differentiated eye cells, such as RPE […]

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors Read More »

Did US Stem Cell Clinic defy FDA injunction? New injured patient suit sparks questions

August 8, 2023 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

It feels like I’ve been writing about the Florida clinic US Stem Cell for a very long time. The FDA has been aware of them for about as long. It was only after reports of patient injuries that the FDA at last took action on US Stem Cell and its subsidiary US Stem Cell Clinic. Several

Did US Stem Cell Clinic defy FDA injunction? New injured patient suit sparks questions Read More »

Weekly reads: MD Stem Cells, embryo models & headaches, cell therapy trial updates

July 2, 2023 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

There is still plenty of reason to worry about unproven stem cells being marketed in the U.S. and elsewhere around the world. I’ll start with a new item here in the U.S. on a firm called MD Stem Cells and end with a newly published paper about how things are going in Poland on this

Weekly reads: MD Stem Cells, embryo models & headaches, cell therapy trial updates Read More »

Stem cell therapy cost in 2024: data & analysis

June 15, 2023 / Professor Paul Knoepfler, Ph.D. / 4 Comments

How much does stem cell therapy cost in 2024? How have prices changed? To authoritatively answer these questions now we need data from the present and past along with expert perspectives. Some surprises come up in this new analysis. In this article Intro | Stem Cell Therapy Cost: $10,000-$20,000 | Why do stem cells cost so much?

Stem cell therapy cost in 2024: data & analysis Read More »

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui

March 19, 2023 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »

In big shift Dr. Robert Lanza exits Astellas

July 28, 2022 / Professor Paul Knoepfler, Ph.D. / 6 Comments

The recent news of Vertex Pharma buying small stem cell biotech ViaCyte and Doug Melton moving to Vertex brought to mind an old stem cell biotech called Advanced Cell Technology (ACT) and its leader, stem cell biologist Dr. Robert Lanza. Years ago, big pharma firm Astellas bought ACT and Lanza moved to be a leader of regenerative

In big shift Dr. Robert Lanza exits Astellas Read More »

Overplaying N=1 in the stem cell therapy world

May 17, 2022 / Professor Paul Knoepfler, Ph.D. / 2 Comments

The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming

Overplaying N=1 in the stem cell therapy world Read More »

Grading my 21 stem cell & regenerative medicine predictions for 2021

December 22, 2021 / Professor Paul Knoepfler, Ph.D. / 3 Comments

The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current

Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best

December 20, 2021 / Professor Paul Knoepfler, Ph.D. / 3 Comments

A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »

New York wins $5.1 million in suit against Manhattan stem cell clinic

November 30, 2021 / Professor Paul Knoepfler, Ph.D. / 5 Comments

There are so many stem cell clinics out there that it can be hard to keep track of them and the news about them, but a big court victory against a Manhattan stem cell clinic by New York State Attorney General Letitia James is notable for several reasons. Injunction on Park Avenue Stem Cell clinic

New York wins $5.1 million in suit against Manhattan stem cell clinic Read More »

Search Results for: vision loss